EP Patent

EP1848402B2 — Rasagiline formulations of improved content uniformity

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2019-02-20 · 7y expired

What this patent protects

Patent listed against rasagiline-mesylate.

Drugs covered by this patent

rasagiline-mesylate (RASAGILINE MESYLATE)

Patent Metadata

Patent number: EP1848402B2
Jurisdiction: EP
Classification: —
Expires: 2019-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Teva Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.